Trial · NCT02619812
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
NCT02619812, Phase 2, Terminated, Mayo Clinic; results first posted 2017-06-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT. Trials, record NCT02619812. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02619812
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
- NCT number
- NCT02619812
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Multiple Myeloma
- Interventions
- Serum-derived bovine immunoglobulin/protein isolate (SBI), Colesevelam, Double Placebo
- First posted
- 2015-12-02
- Last updated
- 2017-06-14
- Results first posted
- 2017-06-14
- Limitations and caveats
- This study was terminated early due to difficulty recruiting subjects; pill burden and nausea were barriers to study continuation for subjects accrued. Data were not collected.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stool Frequency | 30 days | Stool frequency was self reported in a daily bowel pattern diary for 30 days. |
| Primary | Stool Consistency | 30 days | The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Stool Frequency | 30 days | Data were not collected. | ||
| PRIMARY | Stool Consistency | 30 days | Data were not collected. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A: SBI + Placebo | 0 | |
| Overall Study | STARTED | Group B: Colesevelam + Placebo | 0 | |
| Overall Study | STARTED | Group C: Colesevelam + SBI | 1 | |
| Overall Study | STARTED | Group D: Double Placebo | 2 | |
| Overall Study | COMPLETED | Group A: SBI + Placebo | 0 | |
| Overall Study | COMPLETED | Group B: Colesevelam + Placebo | 0 | |
| Overall Study | COMPLETED | Group C: Colesevelam + SBI | 0 | |
| Overall Study | COMPLETED | Group D: Double Placebo | 0 | |
| Overall Study | NOT COMPLETED | Group A: SBI + Placebo | 0 | |
| Overall Study | NOT COMPLETED | Group B: Colesevelam + Placebo | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Group A: SBI + Placebo | 0 | 0 | 0 |
| other | Nausea | Gastrointestinal disorders | Group B: Colesevelam + Placebo | 0 | 0 | 0 |
| other | Nausea | Gastrointestinal disorders | Group C: Colesevelam + SBI | 0 | 1 | 0 |
| other | Nausea | Gastrointestinal disorders | Group D: Double Placebo | 2 | 2 | 2 |
| other | Vomiting | Gastrointestinal disorders | Group A: SBI + Placebo | 0 | 0 | 0 |
| other | Vomiting | Gastrointestinal disorders | Group B: Colesevelam + Placebo | 0 | 0 | 0 |
| other | Vomiting | Gastrointestinal disorders | Group C: Colesevelam + SBI | 0 | 1 | 0 |
| other | Vomiting | Gastrointestinal disorders | Group D: Double Placebo | 1 | 2 | 1 |
| other | Fatigue | General disorders | Group A: SBI + Placebo | 0 | 0 | 0 |
| other | Fatigue | General disorders | Group B: Colesevelam + Placebo | 0 | 0 | 0 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A: SBI + Placebo | ||
| Total, all-cause mortality | Group B: Colesevelam + Placebo | ||
| Total, all-cause mortality | Group C: Colesevelam + SBI | ||
| Total, all-cause mortality | Group D: Double Placebo | ||
| Total, other adverse events | Group A: SBI + Placebo | 0 | 0 |
| Total, other adverse events | Group B: Colesevelam + Placebo | 0 | 0 |
| Total, other adverse events | Group C: Colesevelam + SBI | 1 | 1 |
| Total, other adverse events | Group D: Double Placebo | 2 | 2 |
| Total, serious adverse events | Group A: SBI + Placebo | 0 | 0 |
| Total, serious adverse events | Group B: Colesevelam + Placebo | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02619812
GET https://conductscience.org/api/trials/v1/NCT02619812/events?page=2